Abstract
Background The incidence of early-onset colorectal cancer (EOCRC; <50 years) continues to rise, with the most rapid increases observed among Hispanic/Latino (H/L) populations. Although the TP53 signaling pathway is a critical driver of colorectal tumorigenesis, its prognostic significance in FOLFOX-treated EOCRC—particularly among H/L patients— remains poorly defined.
Methods We analyzed 2,515 colorectal cancer (CRC) cases (H/L = 266; non-Hispanic White [NHW] = 2,249), stratified by ancestry, age at onset, and FOLFOX treatment status. Statistical comparisons were performed using Fisher’s exact, chi-square, and Kaplan–Meier analyses. To enhance integrative data exploration, we applied AI-HOPE and AI-HOPE-TP53, novel conversational artificial intelligence (AI) platforms that enable natural language–driven analysis of multi-dimensional clinical, genomic, and therapeutic data.
Results TP53 pathway alterations were detected in 85% of H/L and 83% of NHW patients treated with FOLFOX. Among late-onset (LO) cases, CHEK2 mutations were significantly lower in H/L patients compared with NHW (0.8% vs. 2.6%, p = 0.02), while TP53 mutations were more frequent in LO NHW patients receiving FOLFOX (78.9% vs. 73.4%, p = 0.04). Within LO NHW cases, FOLFOX-treated patients exhibited an enrichment of TP53 mutations (73.4% vs. 68.1%, p = 0.02) and lower frequencies of ATM (7.2% vs. 12.1%, p = 0.001) and CDKN2A (1.0% vs. 2.5%, p = 0.03) mutations compared to non-FOLFOX-treated counterparts. Across all cohorts, missense mutations represented the predominant alteration type. Remarkably, in EO H/L patients treated with FOLFOX, TP53 pathway alterations were associated with significantly improved overall survival (p = 0.014), an effect not observed in other subgroups.
Conclusions TP53 pathway alterations may serve as an ancestry- and treatment-specific biomarker of favorable prognosis in FOLFOX-treated EOCRC H/L patients. The application of AI-driven integrative analytics through AI-HOPE platforms accelerated biomarker discovery and underscores the potential of conversational AI to advance precision oncology and health equity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Cancer Institute, NCI, award number U2CCA252971; the City of Hope Cancer Control and Population Sciences program by the National Institutes of Health, NIH, National Cancer Institute, NCI, award number P30CA033572; and the Drug Development and Capacity Building: A UCR/CoH-CCC Partnership project by the National Institutes of Health, NIH, National Cancer Institute, NCI, award number U54 CA285116.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source data used in this study were publicly available before the initiation of the study and can be accessed through cBioPortal for Cancer Genomics at https://www.cbioportal.org/ and the GENIE Project (AACR Project GENIE cBioPortal) at https://genie.cbioportal.org. Additional data may be provided upon reasonable request to the authors.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used in the present study is publicly available at https://www.cbioportal.org/ and https://genie.cbioportal.org. The datasets used in our study were aggregated/summary data, and no individual-level data were used. Additional data can be provided upon reasonable request to the authors.
